Mary-Claire King’s name returns regularly in Nobel Prize speculation, but in her account to STAT, the more durable story is what happened after the science entered medicine. King, now 80 and at the University of Washington, described both the odd ritual of being considered for a Nobel and the much more consequential reality that women around the world act on knowledge created by her research.
In 1994 and 1995, King, then a professor at the University of California, Berkeley, showed that breast and ovarian cancer could be hereditary and identified that mutations in the BRCA1 and BRCA2 genes dramatically increased the risk of developing those cancers. That finding turned inherited cancer risk into something clinicians and patients could use.
The clinical impact
King told STAT there is actionable power in knowing whether a patient carries those mutations. Women who test positive can choose preventive mastectomies or have their ovaries and fallopian tubes removed. According to the interview, many have decided to do so, and preventive surgeries have reduced cancer mortality for thousands of women.
That is the real signal behind the long-running Nobel discussion. King’s work did not stop at explaining disease biology; it created a basis for intervention. In biotechnology terms, that is what separates important discovery from scientific prestige alone: a finding changes behavior, clinical pathways, and outcomes.
King described hearing directly from people affected by that shift. She said thousands of women, or their husbands, fathers, and brothers, write to her for clarification and information, forming what she called a huge network of women around the world. She recounted a letter from a woman whose mother died of breast cancer when she was 14, before testing was available. The woman later learned she had a BRCA1 mutation, underwent what King called the necessary surgeries, did not develop breast or ovarian cancer, and sent a photograph of herself with a daughter who had just graduated from high school.
Life as a possible Nobel winner
King said she first realized a Nobel was even a possibility when the Karolinska Institutet invited her to give a seminar some 20 years ago. She later understood the visit as part of the committee’s process for people under consideration. She gave the seminar and then spoke with experts she recognized in retrospect as committee members.
Her description of those conversations is notable for how ordinary the evaluation sounded. Some discussions were, in her view, fascinating and led by people who fully understood the work. Another person, she said, was open about being skeptical that genetics could solve such a problem, while remaining polite and charming. King compared it to any other interview in which a scientist has to be ready for different levels of skepticism and questioning.
She also made clear that the annual ritual does not dominate her routine. Because she is on the Pacific Coast, the announcement comes in the middle of the night, and she told STAT she does not set an alarm for 2 a.m. because the chances in any one year are extremely low.
King’s comments point to a broader truth about biomedical innovation: recognition can be stochastic, but medical value is easier to trace. Her work remains central to cancer prevention because patients and physicians can act on it, whether or not Stockholm ever calls.
